PARP inhibitors enhance replication stress and cause mitotic catastrophe in MYCN-dependent neuroblastoma

New use for an old reagent: Cell cycle analysis of DNA content using flow cytometry in formamide treated cells

(2016) Maurizio Carbonari   CYTOMETRY PART A

Myc induced replicative stress response: How to cope with it and exploit it

(2015) Sara Rohban et al.   Biochimica et Biophysica Acta-Gene Regulatory Mechanisms

The MRN complex is transcriptionally regulated by MYCN during neural cell proliferation to control replication stress

(2015) M Petroni et al.   CELL DEATH AND DIFFERENTIATION

Rad51-mediated replication fork reversal is a global response to genotoxic treatments in human cells

(2015) Ralph Zellweger et al.   JOURNAL OF CELL BIOLOGY

Chromatin to Clinic: The Molecular Rationale for PARP1 Inhibitor Function

(2015) Felix Y. Feng et al.   MOLECULAR CELL

Identification and Pharmacological Inactivation of the MYCN Gene Network as a Therapeutic Strategy for Neuroblastic Tumor Cells

(2014) Olesya Chayka et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

An update on PARP inhibitors—moving to the adjuvant setting

(2014) Amir Sonnenblick et al.   Nature Reviews Clinical Oncology

The role of poly(ADP-ribosyl)ation in DNA damage response and cancer chemotherapy

(2014) M Li et al.   ONCOGENE

Galectin-3 is a marker of favorable prognosis and a biologically relevant molecule in neuroblastic tumors

(2014) V Veschi et al.   Cell Death & Disease

c-MYC-Induced Genomic Instability

(2014) A. Kuzyk et al.   Cold Spring Harbor Perspectives in Medicine

The toxicity of nitrofuran compounds on melanoma and neuroblastoma cells is enhanced by Olaparib and ameliorated by melanin pigment

(2013) Ewan M. McNeil et al.   DNA REPAIR

Oncogenes induce genotoxic stress by mitotic processing of unusual replication intermediates

(2013) Kai J. Neelsen et al.   JOURNAL OF CELL BIOLOGY

Stereospecific PARP Trapping by BMN 673 and Comparison with Olaparib and Rucaparib

(2013) J. Murai et al.   MOLECULAR CANCER THERAPEUTICS

Human RECQ1 promotes restart of replication forks reversed by DNA topoisomerase I inhibition

(2013) Matteo Berti et al.   NATURE STRUCTURAL & MOLECULAR BIOLOGY

Preclinical evaluation of the PARP inhibitor, olaparib, in combination with cytotoxic chemotherapy in pediatric solid tumors

(2013) Robin E. Norris et al.   PEDIATRIC BLOOD & CANCER

Cdc45 Is a Critical Effector of Myc-Dependent DNA Replication Stress

(2013) Seetha V. Srinivasan et al.   Cell Reports

Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors

(2012) J. Murai et al.   CANCER RESEARCH

Inhibition of Poly(ADP-Ribose) Polymerase Enhances the Toxicity of 131I-Metaiodobenzylguanidine/Topotecan Combination Therapy to Cells and Xenografts That Express the Noradrenaline Transporter

(2012) A. G. McCluskey et al.   JOURNAL OF NUCLEAR MEDICINE

The HMGA1 protoncogene frequently deregulated in cancer is a transcriptional target of E2F1

(2012) Isabella Massimi et al.   MOLECULAR CARCINOGENESIS

Topoisomerase I poisoning results in PARP-mediated replication fork reversal

(2012) Arnab Ray Chaudhuri et al.   NATURE STRUCTURAL & MOLECULAR BIOLOGY

Galectin-3 Impairment of MYCN-Dependent Apoptosis-Sensitive Phenotype Is Antagonized by Nutlin-3 in Neuroblastoma Cells

(2012) Veronica Veschi et al.   PLoS One

Functional MYCN signature predicts outcome of neuroblastoma irrespective of MYCN amplification

(2012) L. J. Valentijn et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Molecular mechanisms of MYCN-dependent apoptosis and the MDM2–p53 pathway: an Achille’s heel to be exploited for the therapy of MYCN-amplified neuroblastoma

(2012) Marialaura Petroni et al.   Frontiers in Oncology

The underlying mechanism for the PARP and BRCA synthetic lethality: Clearing up the misunderstandings

(2011) Thomas Helleday   Molecular Oncology

53BP1 nuclear bodies form around DNA lesions generated by mitotic transmission of chromosomes under replication stress

(2011) Claudia Lukas et al.   NATURE CELL BIOLOGY

Exploiting oncogene-induced replicative stress for the selective killing of Myc-driven tumors

(2011) Matilde Murga et al.   NATURE STRUCTURAL & MOLECULAR BIOLOGY

Efficacy of CHK inhibitors as single agents in MYC-driven lymphoma cells

(2011) P T Ferrao et al.   ONCOGENE

RNAi screen of the protein kinome identifies checkpoint kinase 1 (CHK1) as a therapeutic target in neuroblastoma

(2011) K. A. Cole et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

MYCN Sensitizes Human Neuroblastoma to Apoptosis by HIPK2 Activation through a DNA Damage Response

(2010) M. Petroni et al.   MOLECULAR CANCER RESEARCH

Emergence of Micronuclei and Their Effects on the Fate of Cells under Replication Stress

(2010) Koh-ichi Utani et al.   PLoS One

Inhibition of Poly(ADP-Ribose) Polymerase-1 Enhances Temozolomide and Topotecan Activity against Childhood Neuroblastoma

(2009) R. A. Daniel et al.   CLINICAL CANCER RESEARCH

PARP is activated at stalled forks to mediate Mre11-dependent replication restart and recombination

(2009) Helen E Bryant et al.   EMBO JOURNAL

Poor Survival for Infants WithMYCN-Amplified Metastatic Neuroblastoma Despite Intensified Treatment: The International Society of Paediatric Oncology European Neuroblastoma Experience

(2009) Adela Canete et al.   JOURNAL OF CLINICAL ONCOLOGY

Significance ofMYCNAmplification in International Neuroblastoma Staging System Stage 1 and 2 Neuroblastoma: A Report From the International Neuroblastoma Risk Group Database

(2008) Rochelle Bagatell et al.   JOURNAL OF CLINICAL ONCOLOGY

The International Neuroblastoma Risk Group (INRG) Classification System: An INRG Task Force Report

(2008) Susan L. Cohn et al.   JOURNAL OF CLINICAL ONCOLOGY

Distinct transcriptional MYCN/c-MYC activities are associated with spontaneous regression or malignant progression in neuroblastomas

(2008) Frank Westermann et al.   GENOME BIOLOGY